Chandigarh-based RNT Health Insights, a health-tech startup specializing in AI-assisted diagnostics, has received its second US FDA Breakthrough Device Designation for its esophageal cancer detection tool. This innovative solution aids gastroenterologists in identifying both early and advanced stages of esophageal cancer during routine white-light upper GI endoscopy.

Esophageal cancer is a significant global health concern, ranking fourth in cancer-related deaths in India and sixth worldwide, with a survival rate of less than 20% due to late detection. Research suggests early identification can boost survival rates to 90%, yet standard procedures miss up to 25% of early-stage cases.

This recognition underscores RNT Health Insights’ commitment to advancing gastrointestinal diagnostics. The AI-driven tool effectively detects cancer subtypes such as adenocarcinoma and dysplasia, seamlessly integrating into clinical workflows to assist endoscopists while preserving their decision-making authority. By enhancing accuracy and reducing missed cases, it aims to improve patient outcomes.

As part of the FDA Breakthrough Devices Program, this designation accelerates regulatory approvals and facilitates early adoption. Co-founders Tanmaya Gulati and Ria Khurana emphasized the milestone’s significance in transforming gastroenterological diagnostics and improving access to life-saving technologies. RNT Health Insights continues to innovate in AI-assisted medical diagnostics, striving to enhance detection rates and optimize healthcare outcomes.